vs
Side-by-side financial comparison of CF BANKSHARES INC. (CFBK) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $15.7M, roughly 1.8× CF BANKSHARES INC.). CF BANKSHARES INC. runs the higher net margin — 40.0% vs -147.1%, a 187.2% gap on every dollar of revenue. On growth, CF BANKSHARES INC. posted the faster year-over-year revenue change (12.6% vs -67.6%).
CF Bankshares Inc. is a U.S.-based regional bank holding company operating through its community bank subsidiary. It offers a full suite of personal and commercial banking solutions including deposit products, various loan options, wealth management services and digital banking tools, primarily serving individual consumers and small-to-medium business clients across the U.S. Midwest region.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CFBK vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.7M | $28.1M |
| Net Profit | $5.7M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 43.4% | -147.6% |
| Net Margin | 40.0% | -147.1% |
| Revenue YoY | 12.6% | -67.6% |
| Net Profit YoY | 29.9% | -182.8% |
| EPS (diluted) | $0.88 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.7M | $28.1M | ||
| Q3 25 | $15.5M | $32.5M | ||
| Q2 25 | $15.6M | $15.7M | ||
| Q1 25 | $14.1M | $8.0M | ||
| Q4 24 | $14.0M | $86.6M | ||
| Q3 24 | $13.1M | $2.1M | ||
| Q2 24 | $12.6M | $500.0K | ||
| Q1 24 | $12.2M | $0 |
| Q4 25 | $5.7M | $-41.3M | ||
| Q3 25 | $2.3M | $-51.2M | ||
| Q2 25 | $5.0M | $-44.9M | ||
| Q1 25 | $4.4M | $-33.9M | ||
| Q4 24 | $4.4M | $49.9M | ||
| Q3 24 | $4.2M | $-19.1M | ||
| Q2 24 | $1.7M | $-12.5M | ||
| Q1 24 | $3.1M | $-10.3M |
| Q4 25 | 43.4% | -147.6% | ||
| Q3 25 | 17.5% | -163.7% | ||
| Q2 25 | 41.1% | -302.9% | ||
| Q1 25 | 39.5% | -466.3% | ||
| Q4 24 | 36.9% | 54.5% | ||
| Q3 24 | 40.4% | -1051.6% | ||
| Q2 24 | 15.4% | -3068.0% | ||
| Q1 24 | 30.9% | — |
| Q4 25 | 40.0% | -147.1% | ||
| Q3 25 | 15.1% | -157.4% | ||
| Q2 25 | 32.3% | -285.6% | ||
| Q1 25 | 31.4% | -425.7% | ||
| Q4 24 | 35.2% | 57.7% | ||
| Q3 24 | 32.2% | -925.0% | ||
| Q2 24 | 13.5% | -2503.2% | ||
| Q1 24 | 25.2% | — |
| Q4 25 | $0.88 | $-0.41 | ||
| Q3 25 | $0.36 | $-0.52 | ||
| Q2 25 | $0.77 | $-0.46 | ||
| Q1 25 | $0.68 | $-0.35 | ||
| Q4 24 | $0.68 | $0.52 | ||
| Q3 24 | $0.65 | $-0.20 | ||
| Q2 24 | $0.26 | $-0.13 | ||
| Q1 24 | $0.47 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $259.0M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $184.4M | $114.3M |
| Total Assets | $2.1B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | $245.0M | ||
| Q3 25 | $272.4M | $288.2M | ||
| Q2 25 | $275.7M | $240.1M | ||
| Q1 25 | $241.0M | $275.7M | ||
| Q4 24 | $235.3M | $314.0M | ||
| Q3 24 | $233.5M | $204.6M | ||
| Q2 24 | $241.8M | $218.7M | ||
| Q1 24 | $236.9M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $184.4M | $114.3M | ||
| Q3 25 | $179.3M | $147.7M | ||
| Q2 25 | $177.0M | $192.3M | ||
| Q1 25 | $172.7M | $229.0M | ||
| Q4 24 | $168.4M | $256.8M | ||
| Q3 24 | $164.0M | $201.0M | ||
| Q2 24 | $159.6M | $215.2M | ||
| Q1 24 | $158.0M | $223.9M |
| Q4 25 | $2.1B | $327.7M | ||
| Q3 25 | $2.1B | $372.8M | ||
| Q2 25 | $2.1B | $313.5M | ||
| Q1 25 | $2.1B | $327.3M | ||
| Q4 24 | $2.1B | $351.2M | ||
| Q3 24 | $2.1B | $217.6M | ||
| Q2 24 | $2.0B | $222.0M | ||
| Q1 24 | $2.0B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.7M | $-43.5M |
| Free Cash FlowOCF − Capex | $18.2M | — |
| FCF MarginFCF / Revenue | 115.6% | — |
| Capex IntensityCapex / Revenue | 3.1% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $33.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.7M | $-43.5M | ||
| Q3 25 | $5.5M | $-47.0M | ||
| Q2 25 | $8.0M | $-39.6M | ||
| Q1 25 | $2.2M | $-40.7M | ||
| Q4 24 | $14.2M | $42.0M | ||
| Q3 24 | $-1.3M | $-14.5M | ||
| Q2 24 | $4.0M | $-7.3M | ||
| Q1 24 | $-1.2M | $-6.7M |
| Q4 25 | $18.2M | — | ||
| Q3 25 | $5.2M | $-47.2M | ||
| Q2 25 | $7.8M | $-39.6M | ||
| Q1 25 | $2.2M | $-40.8M | ||
| Q4 24 | $13.9M | $41.7M | ||
| Q3 24 | $-1.3M | $-14.6M | ||
| Q2 24 | $4.0M | $-7.3M | ||
| Q1 24 | $-1.2M | $-6.8M |
| Q4 25 | 115.6% | — | ||
| Q3 25 | 33.6% | -145.4% | ||
| Q2 25 | 50.3% | -252.2% | ||
| Q1 25 | 15.2% | -512.1% | ||
| Q4 24 | 99.6% | 48.2% | ||
| Q3 24 | -9.9% | -706.3% | ||
| Q2 24 | 31.6% | -1463.4% | ||
| Q1 24 | -9.5% | — |
| Q4 25 | 3.1% | 0.0% | ||
| Q3 25 | 1.7% | 0.6% | ||
| Q2 25 | 0.7% | 0.3% | ||
| Q1 25 | 0.4% | 1.1% | ||
| Q4 24 | 1.9% | 0.3% | ||
| Q3 24 | 0.2% | 6.8% | ||
| Q2 24 | 0.1% | 7.6% | ||
| Q1 24 | 0.0% | — |
| Q4 25 | 3.26× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 1.58× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 3.21× | 0.84× | ||
| Q3 24 | -0.30× | — | ||
| Q2 24 | 2.35× | — | ||
| Q1 24 | -0.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CFBK
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
